Ionis Pharmaceuticals announced that the U.S. FDA has granted olezarsen Fast Track designation for the treatment of familial chylomicronemia syndrome. Ionis fully enrolled its global Phase 3 BALANCE study of olezarsen in adult patients with FCS last year. The company plans to share data from the BALANCE study in the second half of 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
- Royalty, Ionis enter into royalty agreement for up to $1.1B
- Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis’ genetic medicines and commercial readiness
- Ionis Pharmaceuticals, Royalty Pharma enter $1.1B royalty agreement